MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Search

Charles River Laboratories International Inc

Chiusa

SettoreSettore sanitario

173.53 -0.81

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

172.69

Massimo

173.66

Metriche Chiave

By Trading Economics

Entrata

-332M

-277M

Vendite

-11M

994M

Margine di Profitto

-27.816

Dipendenti

18,300

EBITDA

730K

198M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+17.72% upside

Dividendi

By Dow Jones

Utili prossimi

6 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-78M

7.9B

Apertura precedente

174.34

Chiusura precedente

173.53

Notizie sul Sentiment di mercato

By Acuity

50%

50%

154 / 349 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 apr 2026, 04:27 UTC

Principali Notizie su Eventi

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

3 apr 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

3 apr 2026, 18:30 UTC

Principali Notizie su Eventi

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

3 apr 2026, 18:14 UTC

Discorsi di Mercato

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

3 apr 2026, 17:50 UTC

Discorsi di Mercato

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

3 apr 2026, 17:44 UTC

Acquisizioni, Fusioni, Takeovers

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

3 apr 2026, 16:50 UTC

Principali Notizie su Eventi

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

3 apr 2026, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

3 apr 2026, 16:12 UTC

Utili

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

3 apr 2026, 15:56 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

3 apr 2026, 15:56 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Global Equities Roundup: Market Talk

3 apr 2026, 15:56 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Global Forex and Fixed Income Roundup: Market Talk

3 apr 2026, 15:20 UTC

Principali Notizie su Eventi

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

3 apr 2026, 15:08 UTC

Acquisizioni, Fusioni, Takeovers

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

3 apr 2026, 14:11 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

3 apr 2026, 12:56 UTC

Discorsi di Mercato

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

3 apr 2026, 08:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

3 apr 2026, 08:01 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

3 apr 2026, 08:01 UTC

Discorsi di Mercato

Meituan's Profitability Likely to Improve This Year -- Market Talk

3 apr 2026, 07:45 UTC

Discorsi di Mercato

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

3 apr 2026, 06:17 UTC

Discorsi di Mercato

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

3 apr 2026, 06:17 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

3 apr 2026, 04:33 UTC

Discorsi di Mercato

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

3 apr 2026, 04:33 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

3 apr 2026, 04:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

3 apr 2026, 04:01 UTC

Discorsi di Mercato

Posco Holdings 1Q Earnings Could Fall Short of Expectations -- Market Talk

3 apr 2026, 02:01 UTC

Discorsi di Mercato

India Consumer-Staple Companies Likely to Post Broadly Steady 4Q Results -- Market Talk

3 apr 2026, 01:59 UTC

Discorsi di Mercato

Sea's Shopee E-Commerce Platform Likely in Reinvestment Phase -- Market Talk

3 apr 2026, 01:44 UTC

Discorsi di Mercato

Samsung Likely to Report Record Quarterly Earnings in 2026 -- Market Talk

3 apr 2026, 01:22 UTC

Discorsi di Mercato

Dollar Could Hit 160 Yen in Thin Holiday Trading -- Market Talk

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

17.72% in crescita

Previsioni per 12 mesi

Media 205.89 USD  17.72%

Alto 265 USD

Basso 175 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

8

Acquista

3

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

154 / 349 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat